Occupational Therapists in Goochland, VA Accepting Medicare
4 Occupational Therapists found. Showing 1 - 4
 Anjali Tripathi, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2715 Dogtown Rd, Goochland, VA 23063 Phone: 804-556-4418 Fax: 804-556-4485 |
Colette Rush Walker, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1940 Sandy Hook Rd, Suite F, Goochland, VA 23063 Phone: 904-556-7181 Fax: 804-556-7182 |
Emer Rachel Henry Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3058 River Rd W, Goochland, VA 23063 Phone: 804-657-2043 |
Ms. Ashley Laurin Vice, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2715 Dogtown Rd, Goochland, VA 23063 Phone: 804-556-4418 |
News Archive
electroCore CEO highlights the importance of working with stakeholders when launching new technologies
JP Errico, founder and CEO of electroCore, speaking at The FT Global Pharmaceutical and Biotechnology Conference in London last week, emphasized the importance of working with each of the major stakeholders, i.e., patients and their advocates, key opinion-leading physicians, and decision-makers within the payor community at the earliest opportunity, particularly in regards to innovative and disruptive technology such as electroCore's non-invasive vagus nerve stimulation (nVNS).
Do viruses make bacteria more deadly?
In England and Wales, the national health statistics in 2007 showed that there were 8,324 death certificates which named Clostridium difficile. This is a bacterium which causes severe diarrhoea in humans and animals as the underlying cause of death, a 28% increase from 2006.
Access Pharmaceuticals provides update on its Cobalamin insulin development program
ACCESS PHARMACEUTICALS, INC. provided an update today on its Cobalamin™ oral drug delivery product development programs. The proprietary Cobalamin™ technology utilizes the body's natural vitamin B12 oral uptake mechanism to facilitate oral absorption of pharmaceuticals by a "Trojan horse" mechanism.
Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839
Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.
› Verified 9 days ago
Physical Therapists
Occupational Therapists
Speech-Language Pathologists